Vera Therapeutics said final two-year Phase 3 results for its kidney drug Trutakna (approved under accelerated approval for IgA nephropathy) showed continued stabilization of kidney function and reduced risk of kidney-related death and other complications. Following the FDA’s July accelerated approval, the company plans to pursue full approval during the fourth quarter, using the updated dataset to strengthen the clinical benefit argument. The announcement extends Vera’s push to convert conditional approval into label durability, a step investors and prescribers typically treat as a major inflection point for revenue trajectory.